The US Oncology Network shared on LinkedIn:
“Finding a new way to use an approved cancer treatment is a huge success, especially when it improves outcomes for patients who don’t have any other options.
In this interview with AJMC – The American Journal of Managed Care, Dr. Hans Lee, Director of Multiple Myeloma Research at Sarah Cannon Research Institute (SCRI), discusses the initial results of the LINKER-AL2 study, which shows that linvoseltamab delivers positive results for patients with systemic light chain (AL) amyloidosis. AL amyloidosis is a life-threatening condition that causes organ damage and has no approved treatments after relapse. That makes research into a possible breakthrough therapy extremely important.
Read the full interview here.”
Other articles about The US Oncology Network on OncoDaily.